我国药品上市许可持有人药物警戒职责分析

doi:10.19803/j.1672-8629.2020.10.07

中国药物警戒 ›› 2020, Vol. 17 ›› Issue (10): 681-687.
DOI: 10.19803/j.1672-8629.2020.10.07

我国药品上市许可持有人药物警戒职责分析

孙骏¹, 王佳域¹, 柳鹏程², 于丹丹¹, 王敏娇², 沈梦秋^1,*

¹江苏省药品不良反应监测中心,江苏南京210002;
²中国药科大学,江苏南京 211198

收稿日期:2020-10-14 修回日期:2020-10-14 出版日期:2020-10-15 发布日期:2020-10-13
通讯作者: ^*沈梦秋,女,硕士,主管药师,药品不良反应监测评价。E-mail:sapph0324@163.com
作者简介:孙骏,女,博士,主任药师,上市药品安全性研究。

Pharmacovigilance Duties of Marketing Authorization Holders under of New Drug Administration Law of the People's Republic of China

SUN Jun¹, WANG Jiayu¹, LIU Pengcheng², YU Dandan¹, WANG Minjiao², SHEN Mengqiu^1,*

¹Jiangsu Province Drug Adverse Reaction Monitoring Center, Nanjing Jiangsu 210002, China;
²China Pharmaceutical University, Nanjing Jiangsu 211198, China

Received:2020-10-14 Revised:2020-10-14 Online:2020-10-15 Published:2020-10-13

摘要/Abstract

摘要： 目的梳理我国法律法规中对药品上市许可持有人开展药物警戒工作的职责要求。方法采用文献归纳法对我国法律法规相关内容进行梳理、归纳、总结。结果我国当前对药品注册申请人及药品上市许可持有人在药物警戒工作方面的主要要求为,建立健全药物警戒体系和开展药品风险的监测、识别、评估、控制等具体活动。结论我国应完善药物警戒法律法规体系,做到上下呼应、前后连续、新旧衔接;配套相关细化指南,实施精准化指导,促使持有人有效开展药物警戒活动;合理设计监管路线,加强监管力度,推动药物警戒制度落到实处。

关键词: 药物警戒, 药品管理法, 上市许可持有人, 法定职责

Abstract: Objective To sort out pharmacovigilance duties of MAH according to the new Drug Administration Law of the People's Republic of China. Methods Use the literature induction method to sort out and summarize the relevant content of legal regulations in China. Results The main pharmacovigilance duties of MAA/MAH for applicants and holders in China are to establish and improve the pharmacovigilance system and carry out specific activities such as monitoring, identification, evaluation and control. Suggestions China should improve the legal system of pharmacovigilance, to link up different laws and regulations, provide detailed guidelines and carry out accurate guidance, urge the MAH to effectively carry out pharmacovigilance activities, and rationally design the route of supervision and control, strengthen supervision and promote the implementation of pharmacovigilance system.

Key words: pharmacovigilance, pharmaceutical administration law, holder of drug marketing authorization, statutory duties

中图分类号:

R951

孙骏, 王佳域, 柳鹏程, 于丹丹, 王敏娇, 沈梦秋. 我国药品上市许可持有人药物警戒职责分析[J]. 中国药物警戒, 2020, 17(10): 681-687.

SUN Jun, WANG Jiayu, LIU Pengcheng, YU Dandan, WANG Minjiao, SHEN Mengqiu. Pharmacovigilance Duties of Marketing Authorization Holders under of New Drug Administration Law of the People's Republic of China[J]. Chinese Journal of Pharmacovigilance, 2020, 17(10): 681-687.

参考文献

[1] Ren JT,Zheng WK,Zhang JH,et al.The important role of the manufacturer in the risk management of the drug after the market.[J]Chinese Journal of Pharmacovigilance(中国药物警戒), 2014,11(2): 88-93.
[2] Sun J,Wei Z,Li M.The current situation and thinking on the establishment of adverse drug reaction report and monitoring management system in drug manufacturers[J].Chinese Journal of Pharmacovigilance(中国药物警戒), 2014,11(1):8-11.
[3] Cao LJ,Li XL,Tian CH, et al.Status Quo and Thinking of Post-market Adverse Drug Reaction Reporting by Holders of Drug Marketing Authorization in our country[J].Chinese Journal of Pharmacovigilance(中国药物警戒),2018,15(11): 658-662.
[4] Feng HY,Wu GZ,Fan Y, et al.Analysis of the status quo of post- market drug risk monitoring and control of drug manufacturers in our country[J].Chinese Journal of Pharmacovigilance(中国药物警戒), 2018,15(1): 16-19.
[5] Wang D,Peng LL,Liu CL, et al.Pharmacovigilance analysis and its difference from adverse drug reaction monitoring[J].Chinese Journal of Pharmacovigilance(中国药物警戒), 2017,14(3):150-152, 157.
[6] National Health Commission of the People's Republic of China. Measures for the Administration of Adverse Drug Reaction Reporting and Monitoring (Order No.81 of the Ministry of Health) [EB/OL].(2011-05-04)[2019-11-06].http://www.gov.cn/flfg/2011- 05/24/content_1870110.htm.
[7] National Medical Products Administration.Announcement of the General Administration on the Application of the Secondary Guiding Principles of the International Technical Coordination Committee for the Registration of Drugs for Human Use (No.10 of 2018)[EB/OL].(2018- 01-15)[2019-11-06].http://samr.cfda.gov.cn/WS01/CL0087/ 223345.html.
[8] Center for Drug Evaluation of National Medical Products Admin- istration.Notice on mattersconcerning the "Standards and Procedures for Rapid Reporting of Safety Data During Drug Clinical Trials"[EB/ OL].(2018-04-27)[2019-11-06]..Notice on mattersconcerning the "Standards and Procedures for Rapid Reporting of Safety Data During Drug Clinical Trials"[EB/ OL].(2018-04-27)[2019-11-06].http://www.cde.org.cn/news. do?method=la rgeInfo&id=314529.
[9] Center for Drug Evaluation of National Medical Products Administration.The format and content requirements of the risk management plan when applying for the marketing of anti-tumor drugs[EB/OL].(2018-09-13)[2019-11-06].http://www.cde.org.cn/ dzkw.do?method=largePage&id=314680.
[10] China Food and Drug Administration.Notice of the China Food and Drug Administration on Issuing Regular Drug Safety Update Report Writing Standards[EB/OL].(2012-09-06)[2019-11-06]. http://www.cdr-adr.org.cn/ztzl/dqanxgxbgzl/psurfgwj/201211/ t20121123_5239.html.
[11] China Food and Drug Administration.Letter from the Department of Safety Supervision of China Food and Drug Administration on soliciting opinions on the "Notice on Promoting Production Enterprises to Carry out Key Drug Monitoring Work (Draft for Solicitation of Comments)"[EB/OL].(2013-03-25)[2019-11-06].http://samr.cfda. gov.cn/WS01/CL0288/79321.html.
[12] China Food and Drug Administration.Notice of the China Food and Drug Administration on Issuing Adverse Drug Reaction Reports and Guidelines for Monitoring and Inspection (Trial)[EB/OL]. (2015-07-02)[2019-11-06].http://www.cdr-adr.org.cn/tzgg/ ywgz/201507/t20150721_8228.html.
[13] Central Committee of the Communist Party of China.The General Office of the State Councilissued the "Opinions on Deepening the Reform of the Review and Approval System to Encourage Innovation in Drugs and Medical Devices"[EB/OL].(2017-10-08)[2019-11- 06].http://www.gov.cn/zhengce/2017-10/08/content_5230105.htm.
[14] National Medical Products Administration.Announcement of the National Medical Products Administration on Direct Reporting of Adverse Reactions by Drug Marketing License Holders (No.66 of 2018)[EB/OL].(2018-09-29)[2019-11-06].http://www.cdr-adr. org.cn/xwdt/201810/t20181010_22596.html.
[15] National Medical Products Administration.The Office of the National Medical Products Administration publicly solicits opinions on the guidelines for the collection and reportingof individual adverse drug reactions(draft for comments)[EB/OL].(2018-09-05) [2019-11-06].http://www.nmpa.gov.cn/WS04/CL2051/330159.html.
[16] National Medical Products Administration.Announcement on the issuance of guidelines for clinical safety literature evaluation of marketed drugs (for trial implementation)[EB/OL].(2919-06-04) [2019-11-06].http://www.nmpa.gov.cn/WS04/CL2138/338318.html.
[17] Center for Drug Reevaluation of National Medical Products Administration/National centerfor ADR Monitoring of China. Notice on Publicly Soliciting Opinions on the "Guiding Principles for Writing the Pharmacovigilance Commission Agreement (Draft for Soliciting Comments)"[EB/OL].(2019-11-07)[2019-11-07]. http://www.cdr-adr.org.cn/tzgg_home/201911/t20191107_46748.
[18] Center for Drug Reevaluation of National Medical Products Administration/National centerfor ADR Monitoring of China. Notice on the public solicitation of opinions on the "E2B(R3) Implementation Guidelines for Individual Case Safety Reports(ICSRs) after Listing"(Draft for Comment)[EB/OL].(2018-05-28)[2019-11- 06].http://www.cdr-adr.org.cn/dczj_home/201905/t20190529_ 46066.html.
[19] Center for Drug Reevaluation of National Medical Products Administration/National centerfor ADR Monitoring of China. Notice on Issuing Guidelines for Writing Annual Pharmacovigilance Reports for Drug Marketing Authorization Holders (Trial)[EB/OL]. (2019-11-29)[2019-11-29].http://www.cdr-adr.org.cn/drug_1/ zcfg_1/zcfg_zdyz/201911/t20191129_46859.
[20] National Medical Products Administration.Announcement of the National Medical Products Administration on the application of 15 guidelines for the International Human Drug Registration Technical Coordination Committee including "E1: Population Exposure: Assessing theClinical Safety of Long-term Treatment Drugs for Non-life-threatening Diseases" (2019 No.88)[EB/OL]. (2019-11-05)[2019-11-06].http://www.nmpa.gov.cn/WS04/ CL2138/360014.html.
[21] CIOMS Working Group .Practical Aspects of Signal Detection in Pharmacovigilance: Report of CIOMS Working GroupⅧ[M]. Geneva:Council for International Organizations of Medical Sciences,2010.

我国药品上市许可持有人药物警戒职责分析

Pharmacovigilance Duties of Marketing Authorization Holders under of New Drug Administration Law of the People's Republic of China

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	熊玮仪, 任经天. 抗肿瘤药说明书安全性信息上市后修订的考虑要点[J]. 中国药物警戒, 2024, 21(1): 94-97.
[2]	刘敏, 陈艳, 刘文东, 王海学. 药物临床试验期间安全性数据快速报告的更新与思考[J]. 中国药物警戒, 2024, 21(1): 98-101.
[3]	夏旭东, 黎美霞, 孙阳, 杨胜亚. 药品上市许可持有人药物警戒远程检查流程探讨[J]. 中国药物警戒, 2023, 20(9): 967-970.
[4]	里筱竹, 王蔷, 逄瑜, 张轶菁. 个例药品不良反应报告管理浅析与思考[J]. 中国药物警戒, 2023, 20(9): 975-977.
[5]	逄瑜, 刘博, 吕少俐, 王涛, 邢颖, 秦星宇, 田月洁, 吴文宇. 基于国际药物警戒经验探讨收集患者报告的意义[J]. 中国药物警戒, 2023, 20(9): 978-981.
[6]	沈艳杰, 吴奕卿. 临床试验期间不良事件管理的实践与思考[J]. 中国药物警戒, 2023, 20(9): 982-986.
[7]	刘文东, 崔欢欢, 王晓晗, 苏娴, 王海学. 我国儿童用药临床试验期间药物警戒监管体系现状及思考[J]. 中国药物警戒, 2023, 20(9): 1002-1006.
[8]	张雨琪, 徐昕怡, 朱兰, 朱彦. 药品剂型标准术语的比较研究[J]. 中国药物警戒, 2023, 20(8): 904-910.
[9]	杨乐, 夏东胜, 王涛. 维生素B₆注射剂安全性风险分析[J]. 中国药物警戒, 2023, 20(7): 791-794.
[10]	郑轶, 罗枭, 张朋朋, 刘永梅, 叶小飞, 郭晓晶, 陈霞, 贺佳. 基于主动监测系统的免疫检查点抑制剂心肌炎不良反应探索[J]. 中国药物警戒, 2023, 20(6): 634-638.
[11]	梁士兵, 余泽宇, 孔令垚, 晏利姣, 韩梅, 吴嘉瑞, 刘兆兰, 刘建平. 文献计量法在中药药物警戒领域中的应用价值及展望[J]. 中国药物警戒, 2023, 20(5): 591-594.
[12]	霍佩琼, 郑鹏, 苏振浩. 特殊或重大疾病零售药店开展药物警戒活动的思考[J]. 中国药物警戒, 2023, 20(4): 428-432.
[13]	叶培, 张鹤巍, 吕强, 叶小飞, 许金芳, 郭晓晶. 基于FAERS 数据库舒更葡糖逆转神经肌肉阻滞安全性研究[J]. 中国药物警戒, 2023, 20(3): 321-325.
[14]	田春华, 吴桂芝. 定期获益-风险评估报告在我国的实施思考[J]. 中国药物警戒, 2023, 20(12): 1382-1384.
[15]	雷超, 乔萌, 陈子佳, 张强, 谢雁鸣, 王志飞. 中成药说明书安全性信息项修订的探讨与思考[J]. 中国药物警戒, 2023, 20(12): 1396-1400.